SEC Tracker
Get the app
VERA · XBRL financial data

Vera Therapeutics financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (VERA's year ends in late December)

In thousands of dollarsDec 31, 2021†Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Research and development22,48468,99378,225126,172215,256
General and administrative11,91821,91023,78740,998100,217
Total operating expenses34,40290,903102,012167,170315,473
Operating income (loss)(34,402)(90,903)(102,012)(167,170)(315,473)
Interest income151,7507,97920,71424,479
Interest expense209923,7867,6267,531
Income tax expense (benefit)(1)1111
Net income (loss)(32,609)(89,056)(95,990)(152,148)(299,615)
Earnings per share, basic USD per share(2.43)(3.35)(2.25)(2.75)(4.66)
Earnings per share, diluted USD per share(2.43)(3.35)(2.25)(2.75)(4.66)
Weighted average shares, basic thousands of shares13,43626,57142,70755,32764,234
Weighted average shares, diluted thousands of shares13,43626,57142,70755,32764,234
  • † Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal years (VERA's year ends in late December)

In thousands of dollarsDec 31, 2021†Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents79,67443,45945,68192,646354,725
Marketable securities071,194115,035548,206359,864
Marketable securities, non-current8675811——
Prepaid and other current assets2,86311,04511,30710,36614,294
Total current assets82,537125,698172,023651,218728,883
Property and equipment, net051929601,374
Right-of-use asset7,0005,1732,9493,3721,923
Total assets83,748131,435175,546655,681734,733
Accounts payable1,38511,99111,1187,66521,898
Accrued liabilities5,92810,9648,74916,22331,008
Total current liabilities7,69025,60022,30325,37153,455
Lease liability, non-current03,8311,3952,4681,919
Total liabilities14,15654,52773,86178,526130,212
Accumulated deficit(124,056)(213,112)(309,102)(461,250)(760,865)
Total stockholders' equity69,59276,908101,685577,155604,521
Total liabilities and equity83,748131,435175,546655,681734,733
  • † Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal years (VERA's year ends in late December)

In thousands of dollarsDec 31, 2021†Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(32,609)(89,056)(95,990)(152,148)(299,615)
Stock-based compensation3,0128,88711,49320,80237,926
Depreciation and amortization——21105468
Net cash from operating activities(23,708)(67,596)(92,181)(134,679)(241,104)
Purchases of property and equipment06263972630
Net cash from investing activities(4,204)(70,552)(39,431)(425,029)194,286
Proceeds from issuing common stock51,1762,000———
Share repurchases——0130
Net cash from financing activities53,882101,933133,541606,673308,897
Net change in cash25,970(36,215)1,92946,965262,079
  • † Share count changed about 2x in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Vera Therapeutics48,876not reported(100,253)*72.1M5.0 quarters 10-QJun 30, 2026
Ani Pharmaceuticals360,212266,04456,669*not reported— 10-QJun 30, 2026
Celldex Therapeutics47,45422(57,410)*78.5M12.5 quarters 10-QJun 30, 2026
Travere Therapeutics123,542224,56398,204*96.0M— 10-QSep 30, 2026
Innoviva581,394106,12041,698*71.1M— 10-QSep 30, 2026
Adaptive Biotechnologies75,61583,902not reported161.9M— 10-QSep 30, 2026
Arrowhead Pharmaceuticals54,75975,253(177,469)*141.3M9.0 quarters 10-QJun 30, 2026
Mannkind52,929109,374(18,371)*321.5M6.0 quarters 10-QJun 30, 2026
Schrodinger246,98364,491(47,578)*not reported10.9 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.